Johnson & Johnson

Stocks

JNJ

US4781601046

Market Closed - NYSE Other stock markets 04:00:02 2026-07-17 pm EDT			5-day change	1st Jan Change
253.04 ^USD	+1.23%		-1.53%	+22.27%

Jul. 16	Argus Lifts Johnson & Johnson Price Target to $290 From $275	MT
Jul. 16	Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says	MT

Transcript : Johnson & Johnson Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10

Published on 06/09/2026 at 11:50 am EDT - Modified on 06/09/2026 at 04:51 pm EDT

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Asad Haider (Analysts)

All right. We are just about time, so we can get started with our next session. My name is Asad Haider. I'm the Co-Head of the Healthcare business unit here at

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about Johnson & Johnson

Jul. 16	Argus Lifts Johnson & Johnson Price Target to $290 From $275	MT
Jul. 16	Johnson & Johnson's Innovative Medicine Segment Momentum Continues to Build into 2027, RBC Says	MT
Jul. 16	Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal	RE
Jul. 16	J&J's DePuy Synthes Acquires Expanding Innovations	DJ
Jul. 16	Abbott raises 2026 profit forecast on heart device strength	RE
Jul. 16	Goldman Sachs Adjusts Price Target on Johnson & Johnson to $282 From $275, Maintains Buy Rating	MT
Jul. 16	Stifel Adjusts Price Target on Johnson & Johnson to $260 From $250, Maintains Hold Rating	MT
Jul. 16	Scotiabank Adjusts PT on Johnson & Johnson to $305 From $265, Maintains Sector Outperform Rating	MT
Jul. 16	Raymond James Adjusts PT on Johnson & Johnson to $265 From $258, Maintains Outperform Rating	MT
Jul. 16	Morgan Stanley Adjusts PT on Johnson & Johnson to $294 From $284, Maintains Overweight Rating	MT
Jul. 16	JPMorgan Adjusts Price Target on Johnson & Johnson to $270 From $260, Maintains Neutral Rating	MT
Jul. 16	Wells Fargo Adjusts Price Target on Johnson & Johnson to $272 From $263, Maintains Overweight Rating	MT
Jul. 16	Leerink Partners Adjusts PT on Johnson & Johnson to $276 From $265, Maintains Outperform Rating	MT
Jul. 16	Bernstein Adjusts PT on Johnson & Johnson to $261 From $251, Maintains Market Perform Rating	MT
Jul. 15	Hong Kong Stocks Open Higher as Soft US Inflation Data Lifts Sentiment	MT